Company Overview - Inovio is a clinical stage biotech company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [2][3] - The company has a deep pipeline of therapeutic and vaccine candidates with multiple potential near and midterm catalysts [3] Lead Program - The lead program is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare HPV-related disease [4] - INO-3107 has received breakthrough therapy and orphan drug designations from the FDA and is following the accelerated approval pathway [4] Regulatory Milestones - Inovio expects to complete its Biologics License Application (BLA) submission in the second half of the year, with the goal of FDA acceptance by year-end [5] - The company believes INO-3107 has the potential to become the preferred first-line treatment over the current standard of care, which includes repeated surgery and a recently FDA-approved therapy [5]